Blog Page 93

More U.S. Investment in Biotech Needed, USAID Chief Says The United States and the international community should continue to invest more in the development of new agricultural technologies — including biotechnology — to prevent millions more Africans from becoming malnourished and vulnerable to disease and infection, says Andrew Natsios, administrator of the U.S. Agency for International Development (USAID).

Biotech Investors: When Will They Ever Learn?
Investors should get a grip on reality. Many small companies that were lifted on the latest news are strapped for cash and pursuing risky science that will take years to bear fruit. Even for big players, good trial data on a drug don’t guarantee Food & Drug Administration approval. And once drugs do get approved, most of them face competition in the market.

Drug ads deliver a few side effects Drug companies tripled their advertising budgets in recent years to acquaint American consumers with things like acid reflux disease, depression, erectile dysfunction, and even toenail fungus, a marketing blitz that accounted for roughly 12 percent of the growth in national prescription drug spending in 2000, according to a Harvard University-MIT study released yesterday.